Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML. Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, et al. Blood 2025;146:341-355.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, et al. Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML. Blood 2025;146:341-355.
PMID: 40163809